Abstract
High-modulus asphalt binders are increasingly used to improve rutting resistance and enable pavement thickness reduction. Conventional binder indices do not always capture the stress-dependent response of high-modulus systems under heavy loading, and quantitative rules for selecting a high-modulus additive dosage are still limited. This study develops a full-temperature-range evaluation and dosage determination framework for high-modulus additive-modified asphalt binders (HMABs) produced on an SBS-modified base binder. Four binders were prepared with high-modulus additive dosages of 0%, 17%, 22% and 28% with a binder mass basis. High-temperature performance was evaluated by PG grading and an enhanced MSCR protocol that included 0.1, 3.2, 6.4 and 12.8 kPa. MSCR temperatures were selected based on PG results. Intermediate-temperature performance was evaluated using LAS at 25 °C with VECD-based fatigue analysis on RTFO + PAV-aged binders. Low-temperature cracking was evaluated using ABCD on PAV-aged binders at -36 °C. The results show that the high-temperature PG increased with dosage, but the 22% and 28% binders fell into the same grade, indicating limited dosage discrimination by the PG test. The enhanced MSCR test captured clearer dosage differences under higher stresses. Non-recoverable compliance decreased markedly with dosage, and stress sensitivity showed an overall decreasing trend; 6.4 kPa provided higher dosage sensitivity and lower variability than 3.2 kPa. LAS test shows a non-monotonic fatigue response in which peak shear stress and predicted fatigue life increased up to 22% and then declined at 28%. At 2.5% and 5% strain, the 22% binder increased predicted fatigue life by about 273% and 83% relative to the base binder, while at 10% strain, it was about 11% lower. ABCD results show an upward shift in critical cracking temperature and a clear reduction in fracture stress at high dosages, indicating increasing low-temperature fracture risk. Therefore, high-modulus additives markedly improve high-temperature stability but introduce full-temperature trade-offs. The proposed full-temperature-range examined framework improves performance discrimination and supports dosage selection. A target dosage of 22% is recommended, and 17~22% is suggested as an engineering-controllable range for a balanced full-temperature performance, while 28% should be treated as an upper-bound option, primarily for warm regions where rutting dominates.